Purpose We investigated the relation between carotid artery FDG uptake and cardiovascular risk based on the Framingham risk score (FRS) and evaluated the possible role of FDG uptake in terms of risk stratification of asymptomatic adults. Methods We evaluated 290 adults who underwent FDG PET/ CT as part of general health screens. We calculated target-tobackground ratios, corrected for pre-scan blood glucose levels, and obtained "TBRglu" values for both common carotid arteries. The FRS and the presence/absence of metabolic syndrome were recorded for each subject. Relationships among TBRglu values, metabolic syndrome status, and clinical parameters were assessed. Results Carotid artery FDG uptake was significantly associated with clinical risk factors. Stepwise multiple regression analysis revealed that triglyceride levels, diabetes, and metabolic syndrome were independent determinants of high TBRglu. Of subjects with metabolic syndrome, those exhibiting high carotid artery FDG uptake had significantly higher levels of high sensitivity C-reactive protein (hsCRP). In subjects who did not have metabolic syndrome, FRSs were significantly elevated in those exhibiting high carotid artery FDG uptake compared to those with low uptake (13.1±7.0 vs. 8.2±7.4), as was also true of subjects with the syndrome (21.8 ±16.0 vs. 13.5±11.9).
Introduction
Atherosclerosis is a leading cause of adverse cardiovascular events including angina, myocardial infarction, and stroke. These complications increasingly burden healthcare systems and impair the quality of life. Prevention of cardiovascular disease (CVD) is a serious health issue, and screening for cardiovascular risk is important in clinical practice. However, risk stratification of asymptomatic subjects remains challenging. Although several risk-scoring models have been developed, additional risk indicators are needed [1] .
Recently, [18 F ]-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) has emerged as a powerful noninvasive imaging technique for measuring the vascular inflammation associated with atherosclerosis [2] [3] [4] [5] [6] [7] [8] . Atherosclerosis is a chronic disease in which several processes interact in the vascular endothelium, and development of inflammation is important if atherogenic plaque is to evolve to become vulnerable plaque [9] . Inflammation caused by an increase in the number of activated macrophages within plaque is the key feature increasing the level of vascular FDG uptake in atherosclerosis [10, 11] . Imaging of atherosclerosis using FDG PET yields cellular and molecular information, and the activity of FDG uptake in large arteries and/or aortas may reflect the global plaque burden. Further, increased vascular FDG uptake is associated with traditional cardiovascular risk factors [4, 8] , and regression of FDG uptake has been observed after prescription of statins [6, 12] or lifestyle modification [2] . Therefore, FDG PET/CT shows promise for evaluation and monitoring of atherosclerosis in both symptomatic and asymptomatic subjects.
The prevalence of metabolic syndrome has increased worldwide as more subjects become overweight and obese [13, 14] . Metabolic syndrome is a cluster of interrelated features of metabolic origin, many of which are detectable only in the laboratory, and patients with the syndrome usually have no symptoms. Metabolic syndrome is a potent predictor of future cardiovascular disease and death [15] . Recently, one study found that carotid artery FDG uptake was elevated in subjects with metabolic syndrome, and it was suggested that the syndrome was associated with inflammatory carotid atherosclerosis [16] . However, few studies have been performed to evaluate an association between vascular FDG uptake for metabolic syndrome and cardiovascular risk in asymptomatic populations. We thus investigated the relationship between carotid artery FDG uptake and cardiovascular risk estimated using the Framingham Heart Study risk scoring system (FRS). Further, we evaluated the possible utility of FDG PET/CT data for risk stratification in asymptomatic adults.
Materials and Methods

Study Subjects and Data Collection
The study subjects were 293 consecutive asymptomatic adults who underwent FDG PET/CT as part of general health screening at our institution between January 2012 and July 2012. Of these subjects, we excluded two for whom serum highsensitivity C-reactive protein (hsCRP) measurements were lacking, and one showing intense neck muscle uptake on PET/CT. No subject had any known malignancy, vasculitis, or cerebrovascular or coronary artery disease. The Ethics Committee of our institution approved this retrospective study.
All 290 subjects answered a medical questionnaire assessing smoking status and past medical and current medication history. Height, weight, blood pressure (BP), and waist circumference were measured, and body mass index (BMI) was calculated as the weight/height 2 (kg/m 2 ). Blood tests included measurement of the levels of fasting plasma glucose, hsCRP, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and γ-glutamyl transpeptidase (γ-GT). All measurements and tests were conducted on the same day on which FDG PET/CT was performed.
Hypertension was defined as a systolic BP ≥140 mmHg, a diastolic BP ≥90 mmHg, or use of any anti-hypertensive medication. Diabetes mellitus was defined as a fasting blood glucose level ≥126 mg/dl or use of any hypoglycemic medication. Metabolic syndrome was diagnosed using the criteria established by the American Heart Association/National Heart, Lung, and Blood Institute, using waist circumferences adjusted for Asians. Thus, the syndrome was diagnosed when three or more of the following were present: (1) waist circumference ≥90.0 cm in males and ≥80.0 cm in females; (2) fasting triglycerides ≥150 mg/dl; (3) HDL cholesterol <40 mg/dl in males and <50 mg/dl in females; (4) systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg, or use of antihypertensive medication; (5) fasting plasma glucose ≥100 mg/ dl or use of diabetes medication [17] . Individual 10-year general cardiovascular disease risks were estimated using FRS predictive criteria [18] .
FDG PET/CT
All subjects fasted for at least 6 h before imaging, and the blood glucose level at the time of FDG injection was less than 200 mg/dl in all subjects. PET/CT was performed using Discovery ST (n=142; GE Healthcare, Milwaukee, WI) or Discovery STe scanners (n=148; GE Healthcare). Unenhanced CT scans were collected 60 min after injection of 5 MBq/kg FDG using an 8-or 16-slice helical CT (120 KeV; 30-100 mA in the AutomA mode; section width of 3.75 mm). After CT scanning, emission scans were obtained from the thigh to the skull base for 2.5 min per frame in the three-dimensional (3D) mode. Attenuation-corrected PET images obtained using CT data were reconstructed by a 3D ordered-subsets expectation maximization algorithm (20 subsets, 2 iterations).
Image Analysis
All PET/CT images were reviewed on a workstation (GE Advantage Workstation 4.4, GE Healthcare) by two experienced nuclear medicine physicians. First, we defined the range of the common carotid artery (CCA) on fusion images, beginning from the brachiocephalic trunk or aortic arch and continuing to below the bifurcation site. Next, we manually placed circular or ellipsoidal regions of interest (ROIs) on every slice of transaxial PET images showing the CCA. We included all arterial wall and lumen tissue but excluded adjacent soft tissues. The maximum standardized uptake values (SUVs) of the bilateral CCAs were recorded. Mean SUV values were derived by averaging the maximum SUVs of all slices containing CCAs. To calculate the background activity, the mean SUVs of pooled blood were measured by placing circular ROIs at the mid levels of both jugular veins, and the data were averaged. Target-to-background ratios (TBRs) were calculated by dividing each mean CCA SUV by the blood pool activity. For glucose-corrected parameters, mean SUVs were corrected by individual fasting blood glucose levels prior to scanning to account for a competitive impact of glucose and FDG uptake using an established formula: mean SUVglu = mean SUV × individual blood glucose level (mmol/l)/ 5.0 mmol/l [19, 20] . Finally, the target-to-background ratio corrected by blood glucose level (TBRglu) was calculated by dividing the mean SUVglu by blood pool activity.
Statistical Analysis
Continuous variables are expressed as means±standard deviations in tables and as means±standard errors in histograms.
To compare between-group differences, Student's t-test or the Mann-Whitney U test was used as appropriate when variables were continuous, and the chi-squared or Fisher's exact test when variables were categorical. Correlations were sought using Pearson's or Spearman's test. To determine factors affecting TBRglu values, multiple stepwise regression analysis was performed using SPSS (IBM SPSS Statistics, version 18, IBM Inc., New York, NY). A P value<0.05 was considered to reflect statistical significance.
Results
The clinical characteristics of the 290 subjects are summarized in Table 1 . The mean age was 54.5 years. Of all subjects, 71 (24.5 %) had hypertension, 42 (14.5 %) diabetes, 123 (42.4 %) were current smokers, and 28 (9.7 %) took statins. The mean FRS was 12.0±3.4 %. The mean TBR and TBRglu were 1.3±0.1 and 1.6±1.2, respectively. In the present study, we did not aim to compare TBR and TBRglu; thus, we focused on TBRglu in the article.
Ninety-three subjects (32.1 %) were diagnosed with metabolic syndrome by health screening. Their mean TBRglu was significantly greater than that of subjects without the syndrome (1.5±0.3 vs. 1.3±0.2, P<0.001).
The 75th percentile of TBRglu in all subjects was 1.5, and we chose this value as the threshold for data analysis. Two groups, showing high and low FDG uptake by the carotid arteries, could be distinguished using a TBRglu threshold of 1.5 (Table 1 ). More members of the high uptake group were male (70.8 vs. 49.7 %, P=0.003) and more were obese (high body weight, P=0.003; BMI, P=0.001; waist circumference, P=0.004) than the low uptake group. The former subjects had significantly higher BP (P<0.005); elevated levels of fasting plasma glucose (P<0.001), triglycerides (P=0.001), γ-GT (P=0.014), and hsCRP (P=0.009); and lower levels of HDL TBRglu, target-to-background ratio normalized with blood glucose level; BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; hsCRP, high sensitive C-reactive protein; γ-GT, gamma glutamyl transpeptidase; NS, not significant. Data are presented as mean±SD cholesterol (P=0.001). Also, these subjects exhibited more hypertension (P<0.001), diabetes (P<0.001), and metabolic syndrome (P<0.001) than the low uptake group. In addition, their FRSs were significantly higher (P<0.001). Correlation analysis showed that TBRglu was significantly associated with body weight (P =0.001); BMI (P <0.001); BP (P <0.001); the levels of triglycerides (P < 0.001) and γ-GT (P < 0.001); and the FRS (P<0.001); and negatively associated with the level of HDL cholesterol (P<0.001). In addition, male gender (P < 0.001), diabetes (P < 0.001), metabolic syndrome (P < 0.001), and hypertension (P < 0.001) were significantly associated with high TBRglu.
The results of multiple stepwise linear regression analysis are presented in Table 2 . Diabetes, metabolic syndrome, and triglyceride levels were independent determinants of high TBRglu.
We compared clinical cardiovascular risk factors and FRS data in subjects stratified by the presence of metabolic syndrome and TBRglu (threshold 1.5) ( Table 3 ). Of those without metabolic syndrome, the subgroup with high TBRglu had more males (P=0.006) and a higher frequency of diabetes (P<0.001). Among those with metabolic syndrome, the subgroup with high TBRglu had higher fasting plasma glucose (P<0.001), triglyceride (P=0.011), and hsCRP (P=0.047) levels; diabetes was more common (P<0.001). High uptake subjects with metabolic syndrome had significantly higher levels of hsCRP compared to low uptake subjects with the syndrome (0.23±0.21 vs. 0.14±0.19), whereas the hsCRP level did not differ significantly between subgroups without the syndrome (Fig. 1a) . The FRS was significantly higher in subjects with high uptake compared to both nonsyndromic and syndromic subjects with low uptake (8.2± 7.4 vs. 13.1 ± 7.0; 13.5± 11.9 vs. 21.8± 16.0, respectively; Fig. 1b) . The FRS of subjects with high uptake but no metabolic syndrome was comparable to that of subjects with low uptake and metabolic syndrome (13.1±7.0 vs. 13.5±11.9). Figure 2 demonstrates the representative PET images of a subject without metabolic syndrome but high carotid uptake and a subject with metabolic syndrome but low uptake.
Discussion
In the present study, we found that carotid artery FDG uptake was significantly associated with clinical cardiovascular risk factors and with the 10-year general cardiovascular risk (assessed using the FRS) in an asymptomatic population. As expected, both carotid artery FDG uptake and FRS were elevated in subjects with metabolic syndrome. Of such subjects, the hsCRP level was significantly higher in the high uptake than the low uptake group. Interestingly, among those with metabolic syndrome, the high uptake group had a significantly higher FRS than the low uptake group, whereas the FRS of the low uptake group with metabolic syndrome was comparable to that of the high uptake group without the syndrome.
We analyzed TBRglu along the full lengths of both common carotid arteries. Several studies have found that tumor FDG uptake is diminished during hyperglycemia [21, 22] . Although the need to apply a glucose correction to FDG uptake when noncancerous lesions are being studied is not well understood, one recent study evaluating carotid artery FDG uptake in type 2 diabetes patients observed that glucosecorrected FDG uptake parameters increased significantly as fasting blood glucose levels rose [20] . Consistent with such findings, we noted that glucose-corrected FDG uptake values were significantly higher in hyperglycemic subjects. In addition, we found a weak (r<0.2) and unexpected negative correlation between the presence of diabetes and glucoseuncorrected carotid artery FDG uptake. In addition, 60 of our subjects (20.7 %) had high pre-scan glucose levels (≥120 mg/dl), and we thus used the TBRglu, a glucosecorrected FDG uptake parameter, in our work. Additionally, when we analyzed data using SUVglu, it was significantly associated with FRS (P <0.001), fasting plasma glucose (P<0.001), hypertension (P<0.001), diabetes (P<0.001), and metabolic syndrome (P<0.001). Multiple stepwise regression analysis showed that diabetes and metabolic syndrome were independent determinants of high SUVglu.
We found that high carotid FDG uptake was significantly associated with clinical cardiac risk factors including obesity, dyslipidemia, hypertension, male gender, and diabetes. This is in line with the results of previous investigations [8, 20, 23, 24] . We also found a significant association between carotid FDG accumulation, and the FRS and metabolic syndrome.
Recently, Tahara et al. described a positive association between metabolic syndrome components and FDG uptake in patients with carotid atherosclerosis [16] . Consistent with these data, we found that carotid FDG accumulation was significantly higher in those with metabolic syndrome. Moreover, the hsCRP levels of subjects with high carotid uptake and metabolic syndrome were significantly higher than those of subjects without the syndrome and those of subjects with the syndrome but exhibiting low carotid uptake. The hsCRP TBRglu, target-to-background ratio normalized with blood glucose level; CI, confidence interval level is an indicator of atherosclerotic activity during the initial stages of atherosclerosis [25] . Previous studies found that arterial FDG uptake increased significantly in areas of atherosclerotic plaques that were macrophage-rich histologically [10, 11] . Thus, the carotid artery FDG uptake and hsCRP concentration, both of which are inflammatory markers, reflect active inflammation during early stage carotid atherosclerosis. We thus suggest that development of atherosclerosis may accelerate more markedly in metabolic syndrome subjects with higher rather than lower uptake as hsCRP levels rise. Interestingly, the general cardiovascular FRSs differed significantly when metabolic syndrome subjects were stratified by carotid artery FDG activity. Those with high uptake scored significantly higher. Thus, carotid FDG uptake may help to stratify asymptomatic patients, identifying those needi n g a c t i v e t r e a t m e n t s u c h a s a n t i i n f l am m a t o r y pharmacotherapy. The present study had several limitations. First, although we evaluated cardiovascular risk based on the FRS, our study was cross-sectional and retrospective in nature. A longitudinal study with follow-up is needed. Second, our study population was heterogeneous. We included 42 patients with diabetes and 28 on statin medication. Among those with diabetes, 28 (9.7 %) patients were taking oral hypoglycemic agents at the time of PET/CT, and 14 (4.8 %) were newly diagnosed on screening. Although diabetes has been reported to TBRglu, target-to-background ratio normalized with blood glucose level; BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; hsCRP, high-sensitive C-reactive protein; γ-GT, gamma glutamyl transpeptidase; NS, not significant. Data are presented as mean ± SD Fig. 1 a High-sensitivity Creactive protein (hsCRP) concentrations and b Framingham risk scores (FRSs) in study subjects stratified by the target-to-background ratio corrected for blood glucose level (TBRglu) and presence or absence of metabolic syndrome (MS). Bars: means ± standard errors significantly elevate arterial FDG uptake, we included diabetes patients in our current study because we wished to survey carotid artery FDG uptake in an asymptomatic general population. This is also why we did not exclude those taking statins, which may attenuate arterial FDG uptake. Finally, we only used TBRglu for evaluation of carotid artery FDG uptake in the present study. The index may be affected by the blood glucose level, and the clinical significance of TBRglu has been limited. We are now performing another study in a larger cohort to evaluate carotid artery FDG uptake using TBR, SUVglu, and TBRglu.
Conclusion
High carotid FDG uptake in asymptomatic subjects was significantly associated with the presence of clinical cardiovascular risk factors and an elevated FRS. Of subjects with metabolic syndrome, those exhibiting high carotid uptake had significantly elevated hsCRP levels and FRSs. Therefore, carotid artery FDG activity may serve as a possible biomarker allowing cardiovascular risk stratification of asymptomatic populations. remarkable FDG uptake in bilateral carotid arteries. The Framingham risk score of the subject with high uptake but no metabolic syndrome was comparable with that of the subject with low uptake with metabolic syndrome (11.6 vs. 13.4) 
